COYA · Coya Therapeutics, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-04-09 | Pavao Mark H |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
10,000 |
| 2026-04-01 | Pavao Mark H |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-01-22 | Berman Howard |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service through each vesting date, the shares underlying the option will vest in monthly installments over the next 36 months. Upon a change in control of the Issuer, the shares underlying the option will vest and the option will become immediately exercisable pursuant to the Issuer's 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022. |
Stock Option (right to buy)
|
15,257 |
| 2026-01-22 | Swaminathan Arun |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service through each vesting date, the shares underlying the option will vest in monthly installments over the next 36 months. Upon a change in control of the Issuer, the shares underlying the option will vest and the option will become immediately exercisable pursuant to the Issuer's 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022. |
Stock Option (right to buy)
|
293,983 |
| 2026-01-22 | Grossman Fred |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service through each vesting date, the shares underlying the option will vest in monthly installments over the next 36 months. Upon a change in control of the Issuer, the shares underlying the option will vest and the option will become immediately exercisable pursuant to the Issuer's 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022. |
Stock Option (right to buy)
|
140,041 |
| 2026-01-22 | SNYDER DAVID S |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service through each vesting date, the shares underlying the option will vest in monthly installments over the next 36 months. Upon a change in control of the Issuer, the shares underlying the option will vest and the option will become immediately exercisable pursuant to the Issuer's 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022. |
Stock Option (right to buy)
|
140,041 |
| 2026-01-02 | ROSS WILBUR L JR |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
10,000 |
| 2026-01-02 | Villalobos Anabella |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
10,000 |
| 2026-01-02 | Weinand Dieter |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
10,000 |
| 2026-01-02 | Lee Ann |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
10,000 |
| 2026-01-02 | GOLDSTEIN DOV A MD |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
10,000 |
| 2025-08-18 | GOLDSTEIN DOV A MD |
Director |
Convert↑
|
Common Stock, par value $0.0001 per share
|
17,557 |
| 2025-08-18 | GOLDSTEIN DOV A MD |
Director |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
This option is fully vested. |
Stock Option (right to buy)
|
17,557 |
| 2025-02-25 | Lee Ann |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
5,000 |
| 2025-02-25 | Weinand Dieter |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
5,000 |
| 2025-02-25 | Villalobos Anabella |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
5,000 |
| 2025-02-25 | ROSS WILBUR L JR |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
5,000 |
| 2025-02-25 | GOLDSTEIN DOV A MD |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
5,000 |
| 2025-01-09 | Berman Howard |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest in monthly installments over 36 months commencing on February 9, 2025, subject to continuous service on each vesting date. |
Stock Option (right to buy)
|
150,602 |
| 2025-01-09 | SNYDER DAVID S |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest in monthly installments over 36 months commencing on February 9, 2025, subject to continuous service on each vesting date. |
Stock Option (right to buy)
|
140,562 |
| 2025-01-09 | Swaminathan Arun |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest in monthly installments over 36 months commencing on February 9, 2025, subject to continuous service on each vesting date. |
Stock Option (right to buy)
|
240,964 |
| 2025-01-09 | Grossman Fred |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest in monthly installments over 36 months commencing on February 9, 2025, subject to continuous service on each vesting date. |
Stock Option (right to buy)
|
140,562 |
| 2025-01-01 | Lee Ann |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
5,000 |
| 2025-01-01 | ROSS WILBUR L JR |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
5,000 |
| 2025-01-01 | GOLDSTEIN DOV A MD |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
5,000 |
| 2025-01-01 | Weinand Dieter |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
5,000 |
| 2025-01-01 | Villalobos Anabella |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
5,000 |
| 2024-11-14 | SNYDER DAVID S |
Chief Financial Officer |
Buy↑
|
Common Stock, par value $0.0001 per share
|
1,800 |
| 2024-11-13 | Swaminathan Arun |
Director, Chief Executive Officer |
Buy↑
|
Common Stock, par value $0.0001 per share
|
5,000 |
| 2024-11-11 | Swaminathan Arun |
Director, Chief Executive Officer |
Buy↑
|
Common Stock, par value $0.0001 per share
|
5,000 |
| 2024-11-11 | Grossman Fred |
Chief Medical Officer |
Buy↑
|
Common Stock, par value $0.0001 per share
|
2,710 |
| 2024-06-03 | Berman Howard |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, the shares subject to the option vest in equal monthly installments over a period of 36 months, commencing on July 3, 2024. |
Stock Option (right to buy)
|
163,663 |
| 2024-06-03 | Grossman Fred |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, the shares subject to the option vest in equal monthly installments over a period of 36 months, commencing on July 3, 2024. |
Stock Option (right to buy)
|
70,596 |
| 2024-06-03 | SNYDER DAVID S |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, the shares subject to the option vest in equal monthly installments over a period of 36 months, commencing on July 3, 2024. |
Stock Option (right to buy)
|
70,596 |
| 2024-01-31 | Grossman Fred |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest in 36 equal monthly installments commencing February 29, 2024, subject to continuous service on each vesting date. |
Stock Option (right to buy)
|
81,819 |
| 2024-01-31 | SNYDER DAVID S |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest in 36 equal monthly installments commencing February 29, 2024, subject to continuous service on each vesting date. |
Stock Option (right to buy)
|
81,819 |
| 2024-01-31 | Berman Howard |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest in 36 equal monthly installments commencing February 29, 2024, subject to continuous service on each vesting date. |
Stock Option (right to buy)
|
189,680 |
| 2024-01-31 | Grossman Fred |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option will vest as to 24,689 shares on July 11, 2024, with the remaining shares vesting in 24 equal monthly installments. |
Stock Option (right to buy)
|
74,069 |
| 2024-01-02 | ROSS WILBUR L JR |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of appointment. |
Stock Option (right to buy)
|
10,000 |
| 2024-01-01 | Weinand Dieter |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
5,000 |
| 2024-01-01 | GOLDSTEIN DOV A MD |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
5,000 |
| 2024-01-01 | Villalobos Anabella |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
5,000 |
| 2024-01-01 | Lee Ann |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
5,000 |
| 2024-01-01 | Garren Hideki |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Stock Option (right to buy)
|
5,000 |
| 2023-08-22 | Lee Ann |
Director |
Buy↑
Filing footnotes — Common Stock, par value $0.0001 per share (Indirect)
Represents the weighted average purchase price. The actual purchase prices range from $3.59 to $3.63 per share. The Reporting Person will supply the SEC, the Issuer, or a security holder of the Issuer, with full information regarding the number of shares at each price upon request. |
Common Stock, par value $0.0001 per share
(I)
|
1,000 |
| 2023-08-18 | Weinand Dieter |
Director |
Award↑
|
Stock Option (right to buy)
|
10,000 |
| 2023-08-18 | Weinand Dieter |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2023-07-17 | Grossman Fred |
Chief Medical Officer |
Other↑
|
No Securities Owned
|
0 |
| 2023-07-17 | Grossman Fred |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, 24,689 of the shares subject to the option will vest on July 17, 2024, and the remaining shares will vest in equal monthly installments over a period of 24 months commencing on August 17, 2024. |
Stock Option (right to buy)
|
74,069 |
| 2023-02-27 | Berman Howard |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continuous service, the shares subject to the option vest in equal monthly installments over a period of 36 months commencing on March 27, 2023. |
Stock Option (right to buy)
|
165,000 |